CompletedNCT00401089
Panax ginseng added to antipsychotic treatment for schizophrenia
About this title
Read the official source — NCT00401089Medication studyAges 18–65Canada + United Kingdom
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Kingston and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateDecember 2002
- Recruitment status
- Completed
- Enrollment listed in the registry
- 60
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Canada, United Kingdom
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00401089
- Official title
Show the full official title
A Placebo-controlled Cross Study of Panax Ginseng in Augmentation of Antipsychotics in 60 Partially Treatment Responsive Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Kingston, Canada · St. Thomas, Canada · Thunder Bay, Canada
1 more locations
- Harrow, United Kingdom
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, a research institute.
Did this study involve medication?
Yes. The study involved medication, including Panax Ginseng.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
